Beyond Prescription Volume: Measuring the Pharmacist’s Value

Community pharmacy has no shortage of metrics. Prescription volume, promised wait time, vaccinations, customer ratings, and labor performance can all help leaders monitor operations. In my previous role managing a high-volume chain pharmacy, these measures were part of the daily reality. Prescription count carried particular weight because the number of prescriptions sold could determine a pharmacy’s operational tier and, ultimately, its manager’s bonus opportunity. These measures are understandable: pharmacies must remain efficient, accessible, and financially sustainable. But they capture only part of what pharmacists contribute.

What Prescription Volume Fails to Capture

The problem is not that volume is measured. The problem is what becomes invisible when volume dominates the scorecard. A pharmacist who pauses verification to answer a complex question may worsen a promised-time metric. Calling a prescriber about an interaction, allergy, dose, or more appropriate dosage form can slow the workflow. Walking with a patient to compare over-the-counter products, checking supplements against a medication profile, or teaching someone how to measure blood pressure properly may consume time without producing a billable event. From the patient’s perspective, these actions may be the most valuable part of the encounter. From the dashboard’s perspective, they may look like lost productivity.

I have experienced that conflict repeatedly. In one case, I contacted a prescriber about concomitant clopidogrel and omeprazole therapy and obtained a change to pantoprazole. In another, a patient could not swallow a large amoxicillin-clavulanate tablet, so I worked with the prescriber to change the prescription to a liquid formulation. These were not dramatic interventions, but they made therapy safer or more usable. Neither was adequately represented by the number of prescriptions verified per hour.

Preventive care presents a similar challenge. Vaccination is an essential pharmacy service, but a vaccination target should never replace individualized clinical judgment. Pharmacists must still review age, prior doses, risk factors, timing, travel destination, and current recommendations, then support informed decision-making. Sometimes the appropriate result of that consultation is vaccination; sometimes it is waiting, choosing a different vaccine, or deciding that a requested dose is not routinely indicated. A metric that counts only administered doses cannot recognize the value of a careful assessment that appropriately results in no vaccination.

Making Time for Meaningful Patient Care

The consequences extend beyond isolated encounters. When pharmacists have insufficient time, thorough counseling, medication reconciliation, prescriber communication, and continuing clinical education are often crowded out. Yet patients identify information, communication, trust, and support as important facilitators of medication adherence.¹

Research involving patients with asthma and chronic obstructive pulmonary disease similarly found that perceptions of engagement, medication expertise, and effective communication influenced trust in the pharmacy team.² If those relationships matter to outcomes, they should matter to pharmacy performance systems.

My transition to independent pharmacy changed how I understood this value. I now have access to a private consultation space where I can sit with patients, review their histories, confirm that they understand why they are taking their medications, and discuss adherence concerns without the pressure of a visible queue. I can schedule more focused conversations about hormone therapy, skin care, supplements, and medication routines. In a compounding setting, I can also collaborate on patient-specific considerations such as dosage form and flavor when clinically appropriate and authorized by the prescriber.

The ability to sit is not trivial. A professional environment designed for sustained concentration and private conversation signals that consultation is part of the pharmacist’s job, not an interruption to it. It also gives pharmacists time to review updated guidelines, drug information, safety concerns, and new service opportunities. That learning can benefit the patient while helping the pharmacy identify responsible ways to diversify revenue. Pharmacists should understand the business of pharmacy, but business strategy should make clinical expertise more usable—not push it out of the workflow.

Building Clinical Trust and Business Value

The same principle applies to relationships with prescribers. After joining my current pharmacy, I began reaching out more consistently when I identified meaningful questions involving dosing, therapeutic alternatives, dosage forms, cost, or patient-specific needs.

Over time, the communication became reciprocal. Prescribers began calling me with general medication and formulation questions before making certain treatment decisions. A prescription sent to our pharmacy increasingly represented more than a transaction; it reflected confidence that a known pharmacist would help manage the patient’s medication-related needs.

This professional trust also has business value. When prescribers know that a pharmacist is accessible, responsive, and clinically thoughtful, referrals may follow. Patients who feel known and supported may be more likely to return, ask questions, use appropriate services, and recommend the pharmacy to others.

Evidence from other practice settings suggests that pharmacist services can generate measurable economic value. In one ambulatory-care study, 1334 documented interventions included counseling, drug-utilization review, medication therapy management, and drug information; the investigators estimated an average cost avoidance of $357.62 per intervention.³ That figure cannot be automatically transferred to every community pharmacy, but it demonstrates why documenting clinical work matters. Economic modeling has also suggested that pharmacist prescribing for hypertension could produce substantial health and economic value, while noting that reimbursement remains a barrier.⁴

Measuring Clinical Contributions

Pharmacies therefore need a broader patient-value scorecard. It could track the number and outcome of prescriber interventions; comprehensive consultations; medication reconciliations and synchronization plans; medication-related problems identified and resolved; and follow-up outcomes such as therapy initiation, patient understanding, adherence barriers addressed, and clinical goals achieved. Professional collaboration could also be documented through incoming questions from prescribers, collaborative treatment decisions, and repeat referrals. Raw activity alone is not enough: each intervention should include its reason, clinical significance, action, and outcome so that a new metric does not become another volume contest.

Paid consultation services may be part of the solution, particularly where insurance reimbursement is unavailable or inadequate. However, charging for a service requires a defined scope, appropriate documentation, transparent pricing, and a clear benefit to the patient. Pharmacies should also test whether protected consultation time improves retention, prescriber referrals, service utilization, patient experience, and medication outcomes. The business case should be demonstrated rather than assumed.

Redefining Pharmacy Performance

A pharmacy should be known by its pharmacist because trust is built through consistent professional relationships, not through a logo alone. Patients should know who is responsible for their medication-related care, and prescribers should know whom they can call when a therapy question arises. In that model, the pharmacy becomes a professional care setting as well as a dispensing operation. Prescription count still matters, but it becomes one measure among many—not the definition of success.

What pharmacies choose to measure shapes how pharmacists use their time. If clinical judgment, consultation, collaboration, and resolved medication problems remain invisible to the scorecard, the scorecard will continue to undervalue the pharmacist. Moving beyond prescription volume does not mean abandoning operational discipline. It means measuring the work that makes pharmacy worth having.

References

1. Kvarnström K, Airaksinen M, Liira H. Factors contributing to medication adherence in patients with a chronic condition: a scoping review of qualitative research. Pharmaceutics. 2021;13(7):1100. doi:10.3390/pharmaceutics13071100

2. Te Paske R, van Dijk L, Yilmaz S, Linn AJ, van Boven JFM, Vervloet M. Factors associated with patient trust in the pharmacy team: findings from a mixed method study involving patients with asthma and COPD. Patient Prefer Adherence. 2023;17:3391-3401. doi:10.2147/PPA.S429969

3. Hasham S, Moye-Dickerson P, Thurston MM. Description and financial impact of ambulatory care pharmacy team interventions within an underserved patient population. Am J Health Syst Pharm. 2023;80(suppl 1):S42-S48. doi:10.1093/ajhp/zxac342

4. Dixon DL, Johnston K, Patterson J, Marra CA, Tsuyuki RT. Cost-effectiveness of pharmacist prescribing for managing hypertension in the United States. JAMA Netw Open. 2023;6(11):e2341408. doi:10.1001/jamanetworkopen.2023.41408